78 completed, 11 active not recruiting, 6 recruiting, 3 terminated. 103 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 103 | Completed 78, Active not recruiting 11, Recruiting 6, Terminated 3, Unknown 2, Withdrawn 2, Not yet recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow Plaque Psoriasis: new trials by email Literature Review of Plaque Psoriasis trials Research Report on Plaque Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Clinical Study of QL2106 Injection QL2106 injection, Tremfya® - Plaque Psoriasis | Phase 3 | Active not recruiting | Qilu Pharmaceutical Co., Ltd. | 318 | 2026-05-27 | 2026-10-19 |
| A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis D-2570 Tablet, BMS-986165 Tablet, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | InventisBio Co., Ltd | 477 | 2026-01-12 | 2026-04-29 |
| A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects MC2-01 cream, MC2-01 vehicle, CAL/BDP Gel - Plaque Psoriasis | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 539 | 2025-12-30 | 2026-08-28 |
| A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Zasocitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Takeda | 110 | 2025-12-04 | 2026-09-09 |
| A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis Deucravacitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 366 | 2025-12-03 | 2026-10-27 |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Deucravacitinib, Ustekinumab - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 3040 | 2025-09-22 | 2026-10-28 |
| Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis D-2570, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | InventisBio Co., Ltd | 390 | 2025-09-18 | 2025-12-09 |
| A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis Zasocitinib, Deucravacitinib, Placebo to match zasocitinib - Plaque Psoriasis | Phase 3 | Completed | Takeda | 606 | 2025-07-09 | 2026-05-01 |
| A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy piclidenoson, Placebo - Plaque Psoriasis | Phase 3 | Not yet recruiting | Can-Fite BioPharma | 705 | 2025-06-01 | 2025-04-29 |
| A Study of Switching to Picankibart in Chinese Patients With Plaque Psoriasis With an Inadequate Response to Interleukin-17 Monoclonal Antibody Therapy Picankibart, Secukinumab, Placebo - Plaque Psoriasis | Phase 3 | Active not recruiting | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 308 | 2025-05-27 | 2026-03-25 |
| A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis CT-P55, EU-approved Cosentyx - Plaque Psoriasis | Phase 3 | Active not recruiting | Celltrion | 153 | 2025-05-26 | 2026-02-23 |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 752 | 2025-04-15 | 2026-11-03 |
| Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Open-Label Envudeucitinib, Blinded Envudeucitinib, Placebo - Plaque Psoriasis, Psoriasis (PsO) | Phase 3 | Active not recruiting | Alumis Inc | 1680 | 2025-01-08 | 2026-04-13 |
| Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study Roflumilast Cream 0.3%, Vehicle cream - Plaque Psoriasis | Phase 3 | Completed | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 190 | 2024-11-14 | 2026-07-06 |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis TAK-279 - Plaque Psoriasis | Phase 3 | Active not recruiting | Takeda | 2099 | 2024-09-04 | 2026-06-02 |
| A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Envudeucitinib, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 862 | 2024-08-20 | 2026-10-28 |
| Study of the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of Netakimab in Children With Moderate to Severe Plaque Psoriasis Netakimab, Placebo, Adalimumab - Plaque Psoriasis | Phase 3 | Active not recruiting | Biocad | 140 | 2024-08-08 | 2026-05-27 |
| To Evaluate the Efficacy and Safety of Netakimab in Chinese Patients With Moderate to Severe Plaque Psoriasis Netakimab, Placebo - Plaque Psoriasis | Phase 3 | Completed | SPH-BIOCAD (HK) Limited | 202 | 2024-07-30 | 2026-09-10 |
| A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Envudeucitinib, Apremilast, Placebo - Plaque Psoriasis | Phase 3 | Completed | Alumis Inc | 912 | 2024-07-25 | 2026-10-28 |
| A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) JNJ-77242113, JNJ-77242113 Matching Placebo, Deucravacitinib - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 731 | 2024-03-09 | 2026-11-04 |
Showing 20 of 103. Sign in to see all of them.
Psoriasis (23) · Skin Diseases (4) · Pruritus (3) · Arthritis, Psoriatic (1) · Arthritis, Rheumatoid (1) · Exanthema (1) · Non-alcoholic Fatty Liver Disease (1) · Plaque, Amyloid (1)
Skin and Connective Tissue Diseases (25) · Skin Diseases, Papulosquamous (23) · Skin Diseases (20) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (3) · Skin Manifestations (3) · Arthritis (2) · Joint Diseases (2) · Musculoskeletal Diseases (2) · Autoimmune Diseases (1) · Bone Diseases (1) · Connective Tissue Diseases (1) · Digestive System Diseases (1) · Fatty Liver (1) · Immune System Diseases (1)
Adalimumab (11) · apremilast (11) · Ustekinumab (9) · deucravacitinib (7) · ixekizumab (7) · secukinumab (7) · Etanercept (6) · Certolizumab Pegol (3) · tildrakizumab (3) · CF101 (2) · Dimethyl Fumarate (2) · Fumarates (2) · Methotrexate (2) · N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (2) · Therapeutics (2)
Amgen (8) · Therapeutics, Inc. (7) · Bausch Health Americas, Inc. (6) · Eli Lilly and Company (6) · Janssen Research & Development, LLC (6) · Novartis Pharmaceuticals (5) · Takeda (5) · AbbVie (prior sponsor, Abbott) (4) · Organon and Co (4) · Alumis Inc (3) · Bristol-Myers Squibb (3) · Can-Fite BioPharma (3) · Coherus Oncology, Inc. (3) · UCB Biopharma S.P.R.L. (3) · AbbVie (2)
United States (57) · Canada (37) · Poland (36) · Germany (32) · China (24) · Hungary (22) · Spain (20) · Japan (15) · Australia (14) · France (14) · Bulgaria (12) · Czechia (12) · Italy (12) · South Korea (12) · United Kingdom (12)
Binu J Alexander (3) · Victoria Butners (3) · Anthony Andrasfay (2) · Martin Kaul, MD (2) · Min Zheng (2) · Steven Feldman, MD, PhD (2) · Syd Dromgoole, Ph.D. (2) · Tony Andrasfay (2)
PMID 32531798, PMID 37076998, PMID 37697121, PMID 40600584, PMID 28596043, PMID 29660421, PMID 30915660, PMID 31218661, PMID 31268369, PMID 31424709, PMID 32162721, PMID 32652544, PMID 36098877, PMID 36509889, PMID 37316690, PMID 38123875, PMID 40365708, PMID 40976249, PMID 41838287, PMID 42397072, PMID 14627786, PMID 15948997, PMID 20124563, PMID 21574983, PMID 22348620, PMID 24790410, PMID 26422722, PMID 27500949, PMID 28478975, PMID 29660425, PMID 30054164, PMID 30328108, PMID 30334147, PMID 30471012, PMID 31033034, PMID 31376153, PMID 32207067, PMID 32365251, PMID 32415575, PMID 33060370, PMID 33544883, PMID 33630387, PMID 34192387, PMID 34255891, PMID 34606048, PMID 34657274, PMID 34816373, PMID 34870789, PMID 34879448, PMID 35279805
2023 (6), 2015 (4), 2014 (3), 2019 (2), 2009 (1), 2016 (1), 2025 (1)